home
|
feeds
|
donate
Log in / sign up
neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
Financial Times - news feed
-
Apr 06
neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment